ReviewMolecular oncology2010
Molecular basis for therapy resistance.
Review in Molecular oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Effects of cisplatin on the proliferation, invasion and apoptosis of breast cancer cells following β‑catenin silencing.International journal of molecular medicine · 2020Article
- Effect of quercetin on the anti-tumor activity of cisplatin in EMT6 breast tumor-bearing mice.Obstetrics & gynecology science · 2019Article
- Constitutional Mosaic Epimutations - a hidden cause of cancer?Cell stress · 2019Review
- Regulation of Mucin 1 and multidrug resistance protein 1 by honokiol enhances the efficacy of doxorubicin-mediated growth suppression in mammary carcinoma cells.International journal of oncology · 2016Article
- Autophagy-Mediated Degradation of IAPs and c-FLIP(L) Potentiates Apoptosis Induced by Combination of TRAIL and Chal-24.Journal of cellular biochemistry · 2016Article
- Aminophthalocyanine-Mediated Photodynamic Inactivation of Leishmania tropica.Antimicrobial agents and chemotherapy · 2016Article
- Exosomes-mediate microRNAs transfer in breast cancer chemoresistance regulation.American journal of cancer research · 2016Review
- The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients.International journal of molecular sciences · 2015Review
- Article
- A signaling pathway consisting of miR-551b, catalase and MUC1 contributes to acquired apoptosis resistance and chemoresistance.Carcinogenesis · 2014Article
- A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy.Oncogene · 2014Article
- RAD50 targeting impairs DNA damage response and sensitizes human breast cancer cells to cisplatin therapy.Cancer biology & therapy · 2014Article
- Transcriptional shift identifies a set of genes driving breast cancer chemoresistance.PloS one · 2013Article
- Epidermal growth factor receptor-mediated tissue transglutaminase overexpression couples acquired tumor necrosis factor-related apoptosis-inducing ligand resistance and migration through c-FLIP and MMP-9 proteins in lung cancer cells.The Journal of biological chemistry · 2011Article
- Emerging role of microRNAs in drug-resistant breast cancer.Gene expression · 2011Review
- Article
- Are current development programs realising the full potential of new agents?Breast cancer research : BCR · 2010Article
- On the molecular biology of breast cancer.Molecular oncology · 2010Article
- Molecular basis for therapy resistance.Molecular oncology · 2010Review
- Genetic susceptibility to breast cancer.Molecular oncology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemoresistance remains the main reason for therapeutic failure in breast cancer as well as most other solid tumours. While gene expression profiles related to prognosis have been developed, so far use of such signatures as well as single markers has been of limited value predicting drug resistance. Novel technologies, in particular with regard to high through-put sequencing holds great promises for future identification of the key "driver" mechanisms guiding chemosensitivity versus resistance in breast cancer as well as other malignant conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.